Celcuity announced updated Phase 3 VIKTORIA-1 study results showing that gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved median progression-free survival (PFS) in HR+/HER2- advanced breast cancer patients with PIK3CA mutations compared to alpelisib plus fulvestrant. Notably, patients without liver metastases treated with the gedatolisib triplet had a median PFS of 21.5 months versus 9.1 months for the comparator. The gedatolisib regimens also showed higher objective response rates and longer durations of response, with fewer discontinuations due to adverse events. These findings highlight gedatolisib's potential as a more effective and better-tolerated treatment option in this patient group, with ongoing trials to further evaluate its benefits.
Celcuity's updated Phase 3 VIKTORIA-1 study results on advanced breast cancer patients provide context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Oct 24, 2026 14:41 WIB: out of 150 priced US health-sector stocks, 44 rose and 105 fell. Notable movers include HIMS at USD 27.71 with a 1-day change of -4.87% and a typical hold time on Pluang of 22 days, AMLX at USD 27.20 down 4.80%, and TVTX at USD 50.05 down 4.54%.
Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Compass Therapeutics announced positive Phase 2/3 COMPANION-002 trial results for tovecimig combined with paclitaxel in advanced biliary tract cancer (BTC). The study met its primary endpoint with an 18% response rate versus 5.3% for paclitaxel alone...
Chainlink announced new integrations with GravityChain, reflectmoney, and theorem_markets to enhance blockchain interoperability. These integrations enable seamless token transfers across different blockchains and provide high-speed market data deliv...
Ethereum's deflationary advantage over Bitcoin is weakening as ETH burning rates have dropped sharply and annual supply growth nears Bitcoin's level. However, increased on-chain activity, including higher Ethereum Velocity, more active addresses, and...
